What are the broad-spectrum targeted drugs?

　　Broad-spectrum targeted drugs include Bevacizumab Injection, Erlotinib Hydrochloride Tablets, Everolimus Tablets, Axitinib Tablets, and Ranibizumab Injection, among others. These should be used strictly according to medical advice. Detailed analysis is as follows:

　　1. Bevacizumab Injection: Bevacizumab Injection is a monoclonal antibody drug that targets vascular endothelial growth factor (VEGF). By inhibiting the activity of VEGF, it blocks the formation and growth of tumor blood vessels, thereby cutting off the blood supply to tumors and achieving an anti-tumor effect.

　　2. Erlotinib Hydrochloride Tablets: Erlotinib is an oral anticancer drug belonging to the class of tyrosine kinase inhibitors. It works by inhibiting the activity of epidermal growth factor receptors (EGFR) on tumor cells, thereby blocking tumor cell growth and division, resulting in an antitumor effect.

　　3. Everolimus Tablets: Everolimus is an oral anticancer drug classified as a tyrosine kinase inhibitor. It suppresses tyrosine kinase activity in leukemia cells and other tumor cells, thus inhibiting tumor growth.

　　4. Axitinib Tablets: Axitinib is an oral anticancer drug primarily used in the treatment of malignant tumors such as breast cancer, gastric cancer, and colorectal cancer. As a targeted therapy agent, it inhibits specific signaling pathways within tumor cells, blocking their growth and spread, thereby achieving therapeutic effects.

　　5. Ranibizumab Injection: This drug has broad-spectrum targeting properties and can be used in the treatment of various types of cancer, including gastric cancer, liver cancer, and breast cancer. Its mechanism of action enables it to exert antitumor activity across different tumor types.

　　It should be noted that specific treatment plans and drug selection must be based on individual patient conditions and physician recommendations. Self-medication without medical guidance is not advised.